Navigation Links
Maryland's Cancer Care Community, Patient Advocates Urge State Legislature to Create Parity in Coverage for Preferred Cancer Drugs
Date:2/6/2012

ANNAPOLIS, Md., Feb. 3, 2012 /PRNewswire-USNewswire/ -- Citing the significant quality of life benefits that oral chemotherapy drugs can provide over intravenously (IV) administered chemotherapy, Maryland's cancer community, patient advocacy representatives and patients themselves called on the state legislature this week to pass key legislation that would ensure Maryland's cancer patients are able to access their prescribed chemotherapy regimen of choice.

IV chemotherapy can lead to side effects including pain, hair loss, nausea, vomiting, and anemia, and can lead to added costs and logistical issues as patients must travel to cancer care facilities for treatment. Although oral chemotherapy drugs taken at home often result in fewer side effects, many health insurance plans' coverage of orally administered chemotherapy is prohibitive due to higher copays, expensive deductibles or restrictive coverage limits.

"Oral chemotherapy drugs can often provide substantially greater comfort and convenience than IV administered chemotherapy, and Maryland's cancer patients should have access to the treatments they prefer," said Nancy Davenport-Ennis, founder and CEO of the National Patient Advocate Foundation (NPAF) and the Patient Advocate Foundation (PAF). "We urge Maryland's legislature to create parity in coverage and help individuals fighting cancer access the chemotherapy treatment of their choice without cost being an unrealistic barrier."

The Kathleen A. Mathias Chemotherapy Parity Act of 2012 (Senate Bill 179) would prohibit insurers, nonprofit health service plans, and health maintenance organizations (HMOs) from covering orally administered cancer chemotherapy on terms that are less favorable than coverage for IV administered cancer chemotherapy. The bill is named in honor of the late Kathy Mathias, wife of Sen. Jim Mathias (D-38), who lost her 14-year battle with cancer last August. The legislation currently has 26 cosponsors in the Senate and will be heard before the Maryland House Health and Government Operations Committee on February 9.

In testimony this week before the Maryland Senate Finance Committee, Larry L. Lanier, NPAF Vice President of State Government Affairs, noted that parity in chemotherapy drug coverage remains an important issue for patients, with many contacting PAF on a regular basis in need of assistance to cover the cost of oral chemotherapy medications. Additional testimony was provided by representatives from The Maryland/District of Columbia Society of Clinical Oncology, the Maryland State Medical Society (MedChi), the Leukemia and Lymphoma Society (LLS), additional Maryland-based advocates, and patients who would benefit from the passage of this legislation.

"Senate Bill 179 would help Maryland's cancer patients receive the prescribed chemotherapy treatment of their choice, and could help many individuals experience fewer side effects, maintain their jobs, and spend more time at home with their loved ones during a very challenging time," said Mary Edwards, a registered nurse from Owings Mills who has worked with numerous cancer patients over the years. "We hope that our lawmakers will join the 15 other states and the District of Columbia in passing similar legislation, and help improve Maryland cancer patients' physical and emotional well-being while providing them with the treatment choices they deserve."


'/>"/>
SOURCE National Patient Advocate Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
2. New Study of Primary Liver Cancer Seeks to Enroll 400 French Patients
3. FDA Approves New Skin Cancer Drug First Tested in Arizona by Scottsdale Healthcare and TGen
4. FDA Approves Gleevec For Expanded Use in Patients With Rare Gastrointestinal Cancer
5. Precision Therapeutics Enhances Their Straightforward Approach to Personalizing Cancer Care
6. OncoSec to Present at World Cancer Immunotherapy Conference
7. Signal Genetics Announces Publication of Meta-Analysis of its Colon Cancer Test-Previstage™ GCC Confirming Prognostic Capabilities in Patients with Colon Cancer
8. VentiRx Pharmaceuticals Publishes Preclinical Data of Novel TLR8 Agonist, VTX-2337, Supporting Its Potential as an Immunotherapeutic Approach in Cancer
9. Varian Medical Systems Showcases Advanced Radiotherapy Systems for Treating Cancer at 2012 Arab Health Congress and Exhibition
10. OncoGenex Announces Presentation of OGX-427 Data at the ASCO 2012 Genitourinary Cancers Symposium
11. Phase III Data Show Bayers Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... , Oct. 4, 2017  South Korean-based healthcare product ... training aide "cprCUBE" on Kickstarter. The device will educate ... cardiac arrests with better efficiency compared to the dated ... real-time feedback on efficacy of the compression for a ... has a goal to raise $5,000. ...
(Date:10/4/2017)... , Oct. 4, 2017 OBP ... self-contained, illuminating medical devices, today announced regulatory approval ... Surveillance Agency (or Agência Nacional de Vigilância Sanitária ... single-use, cordless surgical retractor with integrated LED light ... access, illumination and exposure of a tissue pocket ...
(Date:10/2/2017)...  Eli Lilly and Company (NYSE: LLY ... quarter of 2017 on Tuesday, October 24, 2017. Lilly ... with the investment community and media to further detail ... will begin at 9 a.m. Eastern time. Investors, media ... of the conference call through a link that will ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
(Date:10/12/2017)... Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... is holding a treadmill relay – Miles by Moonlight to raise money for the ... donating $300 or more. , Teams will work together to keep their treadmills ...
Breaking Medicine News(10 mins):